Akers Biosciences, Inc. Distribution Agreement (2550J)
April 02 2015 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 2550J
Akers Biosciences, Inc.
02 April 2015
Embargoed: 0700hrs, 2 April 2015
Akers Biosciences, Inc.
Distribution Agreement
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnostics, has signed
an exclusive Master Distributor Agreement with ADS Inc. ("ADS") for
the marketing and supply of Akers' rapid diagnostic assays to U.S.
Government agencies and departments (the "Agreement").
ADS is the premier equipment procurement and support solutions
specialist to the military, law enforcement, first responders and
the defense industries in the United States.
The Agreement, which has an initial term of eighteen months,
spans the entirety of Akers' product catalog but will focus
initially on marketing the Company's rapid test for Heparin-Induced
Thrombocytopenia (an allergic condition associated with the
commonly used blood-thinner Heparin, generally used in various
surgical procedures); the Company's rapid, light-weight test for
determining blood type compatibility in remote locations; and the
Company's range of rapid tests for infectious diseases including
Malaria and Dengue Fever.
"Akers and ADS have identified a number of areas in which U.S.
Government departments such as the Department of Defense could
benefit significantly from the introduction of the Company's rapid
diagnostic assays," said Raymond F. Akers, Jr. PhD, Co-founder and
Executive Chairman of the Board.
"These include the introduction of the Company's PIFA
Heparin/PF4 rapid assays to military hospitals in order to reduce
the costs and risks associated with the use of Heparin as an
blood-thinning agent; our rapid blood-typing card for use in blood
transfusions under battlefield conditions; and tests for infectious
diseases such as Malaria and Dengue Fever out in the field or in
remote locations where speed and ease of diagnosis are of paramount
importance," continued Dr. Akers.
"ADS is the preeminent distributor to this important target
market so we are delighted to partner with them through this
agreement to reach these large potential customers," added Dr.
Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effectivehealthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio
ABOUT ADS INC.
ADS Inc. is a leading solutions provider that proudly serves all
branches of the U.S. Military, federal, state and local government
organization, law enforcement, first responders, foreign
governments and the defense industry. The company is focused on
solving customers' challenges through the largest product and
service selection, the broadest array of procurement and contract
options, world-class support and logistics solutions and legendary
customer service. ADS is a single source that actively seeks out
customers' equipment and logistics challenges to deliver innovative
and cost-effective solutions that help them complete their mission
and maintain readiness. ADS equipment and support solutions include
C4ISR, Combat Support, Medical, Operational Clothing and Individual
Equipment (OCIE), Weapons and Optics as well as Special Missions,
including CWMD, CBRNe EOD, First Responders and Maritime
Operations.
Additional information can be found at www.adsinc.com.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAFLFELLSEAF
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Sep 2023 to Sep 2024